Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints.
Non-alcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and a disease with high unmet medical need. Platform trials provide great benefits for sponsors and trial participants in terms of accelerating drug development programs. In this article, we desc...
Saved in:
| Main Authors: | Elias Laurin Meyer, Peter Mesenbrink, Nicholas A Di Prospero, Juan M Pericàs, Ekkehard Glimm, Vlad Ratziu, Elena Sena, Franz König, EU-PEARL NASH Investigators |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0281674&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Motion – All Patients with NASH Need to Have a Liver Biopsy: Arguments against the Motion
by: Jacqueline Laurin
Published: (2002-01-01) -
Assessing the potential causal effects of 1099 plasma metabolites on 2099 binary disease endpoints
by: Xianyong Yin, et al.
Published: (2025-03-01) -
Why and how should we simulate platform trials? Learnings from EU-PEARL
by: Elias Laurin Meyer, et al.
Published: (2025-01-01) -
Jennifer Nash, Birthing Black Mothers.
by: Juanita Stephen
Published: (2022-12-01) -
Nash equilibria in the context of convex sets
by: Daina Sūdžiūtė
Published: (2001-12-01)